Kenichi Furuya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenichi Furuya has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Masashi Takano
Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
9 shared publications - Morikazu Miyamoto
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359‑8513, Japan
9 shared publications - Hiroaki Soyama
Department of Obstetrics and Gynecology, Takanohara Central Hospital
8 shared publications - Tadashi Aoyama
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan
6 shared publications - Tomoyuki Yoshikawa
Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan
6 shared publications - Hiroko Matsuura
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan
4 shared publications
Latest Publications
- 19 June 2019
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 39 (7) , 1022-1024
A case of spontaneous ovarian hyperstimulation syndrome after vaginal delivery
- 19 June 2019
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 39 (7) , 1022-1024
A case of spontaneous ovarian hyperstimulation syndrome after vaginal delivery
- 9 May 2019
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (10) , 1273-1283
Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma
This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma.
- 9 May 2019
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (10) , 1273-1283
Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma
This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma.
- 2 March 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (5) , 809-814
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem).
- 2 March 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (5) , 809-814
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem).
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (2) , e20
Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis
Miyamoto M, et al. J Gynecol Oncol. 2017 Dec;29(2):e20. https://doi.org/10.3802/jgo.2018.29.e20
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (2) , e20
Open AccessSeromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis
Miyamoto M, et al. J Gynecol Oncol. 2017 Dec;29(2):e20. https://doi.org/10.3802/jgo.2018.29.e20
- 22 November 2017
- Published by Springer Nature in Medical Oncology
- Vol. 34 (12) , 201
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin
High-temperature-required protein A2 (HtrA2) is one of the serine proteases related to apoptosis. HtrA2 protein expression has been associated with cisplatin resistance and poor prognosis in ovarian serous adenocarcinoma (SAC). The aim of this study was to understand the influence of HtrA2 on repeated treatment with cisplatin. The change in HtrA2 expression in 31 ovarian cancers was investigated by immunohistochemical analysis, before and after cisplatin-based chemotherapy, and the association between HtrA2 expression after chemotherapy and prognosis was analyzed. The association between the change in HtrA2 and proteins associated with LATS1 in ovarian serous cancer cell lines after repeated treatment with cisplatin was evaluated in vitro. In immunohistochemical analysis, repeated cisplatin treatment induced downregulation of HtrA2 protein expression, before and after cisplatin-based chemotherapy in SAC. Progression-free survival and overall survival of SAC with low expression of HtrA2 were worse than those with high expression. In vitro analysis using cisplatin-sensitive ovarian cancer cell lines, KF28, and cisplatin-resistant cancer cell lines, KFr13, obtained from KF28 by repeated cisplatin treatment, showed that HtrA2 protein expression was lower in KFr13 than in KF28. Furthermore, KFr13 had a higher invasive capacity than KF28. Next, downregulation of HtrA2 transfected with an HtrA2-specific siRNA in KF28 had not only cisplatin resistance, but also more invasive capacity than those with non-specific siRNA. Repeated treatment with cisplatin downregulated the HtrA2 protein, which led to cisplatin resistance and increased invasive capacity. Thus, HtrA2 might be a biomarker of response to cisplatin treatment and prognosis, after cisplatin-based chemotherapy.
- 22 November 2017
- Published by Springer Nature in Medical Oncology
- Vol. 34 (12) , 201
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin
High-temperature-required protein A2 (HtrA2) is one of the serine proteases related to apoptosis. HtrA2 protein expression has been associated with cisplatin resistance and poor prognosis in ovarian serous adenocarcinoma (SAC). The aim of this study was to understand the influence of HtrA2 on repeated treatment with cisplatin. The change in HtrA2 expression in 31 ovarian cancers was investigated by immunohistochemical analysis, before and after cisplatin-based chemotherapy, and the association between HtrA2 expression after chemotherapy and prognosis was analyzed. The association between the change in HtrA2 and proteins associated with LATS1 in ovarian serous cancer cell lines after repeated treatment with cisplatin was evaluated in vitro. In immunohistochemical analysis, repeated cisplatin treatment induced downregulation of HtrA2 protein expression, before and after cisplatin-based chemotherapy in SAC. Progression-free survival and overall survival of SAC with low expression of HtrA2 were worse than those with high expression. In vitro analysis using cisplatin-sensitive ovarian cancer cell lines, KF28, and cisplatin-resistant cancer cell lines, KFr13, obtained from KF28 by repeated cisplatin treatment, showed that HtrA2 protein expression was lower in KFr13 than in KF28. Furthermore, KFr13 had a higher invasive capacity than KF28. Next, downregulation of HtrA2 transfected with an HtrA2-specific siRNA in KF28 had not only cisplatin resistance, but also more invasive capacity than those with non-specific siRNA. Repeated treatment with cisplatin downregulated the HtrA2 protein, which led to cisplatin resistance and increased invasive capacity. Thus, HtrA2 might be a biomarker of response to cisplatin treatment and prognosis, after cisplatin-based chemotherapy.
- 9 November 2017
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (1) , 111-117
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review
We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for recurrent and refractory endometrial carcinoma, administered based on UGT1A1 genotype.
- 9 November 2017
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (1) , 111-117
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review
We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for recurrent and refractory endometrial carcinoma, administered based on UGT1A1 genotype.
- 29 May 2017
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 43 (8) , 1346-1349
Multiple placental surface cysts with intracystic hemorrhaging: A case report and review of the literature
A placental surface cyst is a cystic mass arising from the surface of the placenta. It is seldom complicated by intracystic hemorrhaging and the clinical importance of this kind of case is unclear. Therefore, we present a case of a placental surface cyst with intracystic hemorrhaging. A 29‐year‐old multiparous woman was diagnosed with multiple placental surface cysts with threatened preterm birth and fetal growth restriction on ultrasonography at 26 gestational weeks (GW). At 31 GW, the hemorrhage was identified inside the cyst. At 32 GW, she presented with placental abruption, and emergency cesarean section was performed. Both the mother and her baby survived. Placental surface cysts up to 77 × 65 mm in diameter containing old hemorrhages were discovered, and pathological examination revealed hemosiderin and fibrin deposition. Pregnancy with a placental surface cyst with intracystic hemorrhaging may have the potential for severe obstetric complications.
- 29 May 2017
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 43 (8) , 1346-1349
Multiple placental surface cysts with intracystic hemorrhaging: A case report and review of the literature
A placental surface cyst is a cystic mass arising from the surface of the placenta. It is seldom complicated by intracystic hemorrhaging and the clinical importance of this kind of case is unclear. Therefore, we present a case of a placental surface cyst with intracystic hemorrhaging. A 29‐year‐old multiparous woman was diagnosed with multiple placental surface cysts with threatened preterm birth and fetal growth restriction on ultrasonography at 26 gestational weeks (GW). At 31 GW, the hemorrhage was identified inside the cyst. At 32 GW, she presented with placental abruption, and emergency cesarean section was performed. Both the mother and her baby survived. Placental surface cysts up to 77 × 65 mm in diameter containing old hemorrhages were discovered, and pathological examination revealed hemosiderin and fibrin deposition. Pregnancy with a placental surface cyst with intracystic hemorrhaging may have the potential for severe obstetric complications.
- Open Access
- 1 January 2017
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 28 (3) , e33
Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas
Miyamoto M, et al. J Gynecol Oncol. 2017 Mar;28(3):e33. https://doi.org/10.3802/jgo.2017.28.e33
- 1 January 2017
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 28 (3) , e33
Open AccessInhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas
Miyamoto M, et al. J Gynecol Oncol. 2017 Mar;28(3):e33. https://doi.org/10.3802/jgo.2017.28.e33
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 5583
Combination therapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: A phase II study with biomarker analysis.
5583 Background: Recurrent clear cell carcinoma (RCCC) of the ovary showed exceedingly chemo-resistant phenotype, especially in the case with recurrent or refractory to previous therapy. A phase II trial to evaluate the effect of combination therapy with temsirolimus and trabectedin for patients with RCCC was performed. Methods: Eligible patients were as follows: (a) ECOG PS = 0~2 (b) histologically confirmed ovarian clear cell adenocarcinoma (c) diagnosed as platinum-resistant ovarian cancer (d) written informed consent. Patients with RCCC were treated with weekly regimen using two drugs: 15mg/m2 of temsirolimus and 0.15mg/m2 of trabectedin (3 weeks, one week rest). Treatment was continued until development of progressive disease (PD) or unmanageable adverse effects. There was no significant difference of serum level of VEGF according to the response evaluation. Biomarker analyses including serum VEGF and BNP were also conducted. Results: A total of 21 patients were analyzed in the present study. There w...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 5583
Combination therapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: A phase II study with biomarker analysis.
5583 Background: Recurrent clear cell carcinoma (RCCC) of the ovary showed exceedingly chemo-resistant phenotype, especially in the case with recurrent or refractory to previous therapy. A phase II trial to evaluate the effect of combination therapy with temsirolimus and trabectedin for patients with RCCC was performed. Methods: Eligible patients were as follows: (a) ECOG PS = 0~2 (b) histologically confirmed ovarian clear cell adenocarcinoma (c) diagnosed as platinum-resistant ovarian cancer (d) written informed consent. Patients with RCCC were treated with weekly regimen using two drugs: 15mg/m2 of temsirolimus and 0.15mg/m2 of trabectedin (3 weeks, one week rest). Treatment was continued until development of progressive disease (PD) or unmanageable adverse effects. There was no significant difference of serum level of VEGF according to the response evaluation. Biomarker analyses including serum VEGF and BNP were also conducted. Results: A total of 21 patients were analyzed in the present study. There w...
- 1 January 1992
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 45 (1) , 33-36
Prostaglandins and premenstrual syndrome
- 1 January 1992
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 45 (1) , 33-36
Prostaglandins and premenstrual syndrome